Quince Therapeutics (NASDAQ:QNCX – Get Rating) and Genocea Biosciences (NASDAQ:GNCA – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.
Profitability
This table compares Quince Therapeutics and Genocea Biosciences' net margins, return on equity and return on assets.
Get Quince Therapeutics alerts:| Net Margins | Return on Equity | Return on Assets | |
| Quince Therapeutics | N/A | -71.16% | -64.87% |
| Genocea Biosciences | N/A | -182.88% | -62.76% |
Earnings and Valuation
This table compares Quince Therapeutics and Genocea Biosciences' top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quince Therapeutics | N/A | N/A | -$89.94 million | ($2.74) | -0.31 |
| Genocea Biosciences | $1.64 million | 0.21 | -$33.20 million | ($0.61) | -0.01 |
Analyst Recommendations
This is a summary of recent recommendations for Quince Therapeutics and Genocea Biosciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quince Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Genocea Biosciences | 0 | 2 | 0 | 0 | 2.00 |
Genocea Biosciences has a consensus price target of $3.00, suggesting a potential upside of 50,747.46%. Given Genocea Biosciences' higher probable upside, analysts plainly believe Genocea Biosciences is more favorable than Quince Therapeutics.
Insider & Institutional Ownership
31.9% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 9.3% of Genocea Biosciences shares are owned by institutional investors. 27.9% of Quince Therapeutics shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk and Volatility
Quince Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.
Summary
Genocea Biosciences beats Quince Therapeutics on 7 of the 10 factors compared between the two stocks.
About Quince Therapeutics
(Get Rating)
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
About Genocea Biosciences
(Get Rating)
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
Receive News & Ratings for Quince Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quince Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.